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Data were retrospectively collected at several points in time from medical records
and hospital information systems on baseline characteristics, treatments, dosages,
treatment response, survival, adverse events and resource use. All patients entered
the registry at time of diagnosis. RESULTS: Our registries contained information of
615 mRCC and 3093 haematological cancer patients (non-Hodgkin, multiple my-
eloma, and chronic lymphocytic leukaemia). They provided important information
about how patients, including those regularly excluded from clinical trials, are
treated in daily practice. However, important data, including prognostic informa-
tion, was commonly missing (e.g. 40-55% missing performance status). Further-
more, patients treated with the drug of interest were not comparable to patients
not treated with this drug. Moreover, only small numbers of patients received the
drug of interest (mRCC: N34; non-Hodgkin: N35), and many patients received
different drugs in various combinations and treatment sequences in haematologi-
cal cancers. This, in combination with the inability to fully correct for confounding,
complicates the estimation of a real-world incremental cost-effectiveness
estimate. CONCLUSIONS: Our registries provided important information to physi-
cians and policymakers to enhance quality of care and facilitate evidence-based
decision making. Although population-based registries include high numbers of
patients, it remains a challenge to obtain sufficient numbers of similarly treated
and comparable patients. Therefore, it is inevitable to use data synthesis in com-
bination with comprehensive modelling techniques to obtain valid real-world in-
cremental cost-effectiveness estimates.
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IS SALE OF TOBACCO AND SMOKING PREVALENCE PREDICTORS OF FUTURE
LUNG CANCER INCIDENCE?
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OBJECTIVES: Smoking is a leading cause of early dead and morbidity in the West-
ern World. The purpose of this study is to evaluate how tobacco sales and tobacco
survey data correlates with lung cancer incidence in the Danish population. It is
estimated that up to 86% of lung cancer cases in developed countries are smoking
related. METHODS: Lung cancer incidence data from 1943-2009 are from Nordcan
(www.ancr.nu). Sale of tobacco (cigarettes/inhabitant) 1920-2010. Smoking habit
surveys from 1953-2010, annually from 1969. Lung cancer incidence is age stan-
dardized to the Nordic population (ASR(N)), and is in rate per 100.000/year. Corre-
lations are analyzed with Spearman’s rho with SPSS18. RESULTS: The strongest
correlation (spearman’s rho  0.92, p0.0001) is found between sale of cigarettes
and incidence of lung cancer with a lag time of 24 years. The correlation between
lung cancer and the proportion of the population that smokes is well correlated for
men (0.8, p0.0001, lag time20 years). Female smokers and lung cancer are with
a lag time of 5-26 years negatively correlated, but correlates positively when the lag
time is more than 27 years, the best correlation being 0.732 (p0.039, lag time35
years).CONCLUSIONS: The correlation between lung cancer incidence and the sale
of cigarettes is better than for the proportion of smokers. This might be because
sale gives a better estimation of the overall exposure in a form of population “pack
years”. The negative correlation between the proportion of female smokers and
lung cancer, and the change to a positive correlation when a longer lag time is
applied can be either a true finding that might be explained by longer development
time in females. Or it could be a result of changes in the accuracy of the proportion,
or a result of changes in the age pattern.
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OBJECTIVES: The new value-based system of pricing branded medicines in the UK
is nearing the launch phase with unresolved concerns towards developing the new
pricing framework and executing the system. This study identifies the strategies
proposed by stakeholders for the successful implementation of VBP and also de-
termines the ‘relative importance weights’ of additional value-elements i.e., bur-
den of illness, innovation and societal benefit introduced in the new pricing
framework. METHODS: In-depth qualitative and survey-based interviews were
conducted with 23 experts identified in pharmaceutical industry, NHS and SMC
advisory committees, NHS hospitals and pharmacies. RESULTS: Pharmaceutical
industry should adapt to a new model that brings innovation in R&D, addresses
unmet need and demonstrates the value of a new drug by gathering real-world
evidence. Government or payers should proactively publish guidelines before the
launch or propose a transitional arrangement for pharma in 2014. The local uptake
of medicines should be encouraged by introducing national settlement schemes
and incentivizing the local commissioning groups. It is possible that government
and pharmaceutical industry will direct more efforts towards improving the inter-
action between prescribers and patients for gathering real-world evidence. The
results also indicated that clinical-effectiveness and cost-effectiveness will remain
the prime metric in valuation process, however, burden of illness and innovation
may carry more weight than other value-elements. Societal benefit still needs to be
broadly defined; and innovation should ultimately translate into improved clinical
efficacy. The study also highlights the impact of VBP on each stakeholder group and
across disease areas with a focus on primary care and oncology. CONCLUSIONS:
The stakeholders still lack the clear understanding of VBP and believe that ulti-
mately it might be restructuring of the existing system given the limited time left
for its implementation. Even though the new pricing framework includes addi-
tional criteria, pricing decisions are anticipated to be made on a case-by-case basis
eventually.
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OBJECTIVES: Patient access or risk sharing schemes (PASs) have recently been
increasingly used, enabling easier and swifter access to new treatments, especially
in oncology. However, PASs frequently do not deliver the required results. The aim
was to create a conceptual framework that allows the selection of the most appro-
priate PAS in different countries. METHODS: A targeted literature review has been
conducted to identify PAS specific literature in oncology. Based on the review and
the evaluation of the currently implemented PASs in the EU, a three-level concep-
tual framework has been constructed. It is based on a list of criteria identified as
country-specific prerequisite for the different types of PASs. Each criterion can be
achieved by different tools/techniques, each with a list of basic requirements. PASs
for each country can be evaluated using simple scoring system for each criterion.
The proposed framework has been validated by EU industry experts and payer’s
representatives and tested for the UK and Hungary.RESULTS:The literature review
identified large number of abstracts and studies; however only 14 met the inclusion
criteria. These were mainly from the UK and US. The criteria evaluated authorities’
roles and responsibilities, transparency throughout the negotiation process and
implementation phase for all stakeholders, presence of trust and cooperation
among payers and manufacturers, availability of budget, clear patient pathways,
data availability, administration capacity and appropriate incentives for the stake-
holders. The test results were in accordance with the expert’s views and empha-
sized the insights from recent experiences and case studies. CONCLUSIONS: The
conceptual framework offers a good starting point for the evaluation of the poten-
tial success of the different PASs in oncology in a given country. Future steps could
include extension of therapeutic area, incorporation of relative weights for the
criteria and extending the countries used for validation.
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OBJECTIVES: We evaluated the use of confirmatory HER2 fluorescence in situ hy-
bridisation (FISH) and predictors of trastuzumab use in early-stage breast cancer
(ESBC) in the province of Ontario. The adherence of practice patterns to provincial
adjuvant trastuzumab treatment guidelines and national HER2 testing consensus
guidelines was assessed. METHODS: A retrospective cohort of ESBC patients diag-
nosed in 2006-7 was identified in the Ontario Cancer Registry (OCR). HER2 test type,
sequence, result(s) and status, tumour grade and hormone receptor status were
determined from centrally-held (OCR) pathology reports. Trastuzumab treatment
was determined from provincial cancer agency records. Demographic, local health
integration network (LHIN), surgical, prior radiological and anthracycline treat-
ment and comorbidity data were determined from administrative data sources.
Logistic models were used to estimate adjusted odds ratios for factors associated
with guideline adherence. RESULTS: The first HER2 test result was the largest
predictor of confirmatory testing, with HER2 equivocal tumours being significantly
more likely to be retested vs. positive (OR 116 [79, 169]). Confirmatory testing varied
by LHIN but not by age. Patients diagnosed with stage III disease had significantly
higher odds of receiving a confirmatory test vs. stage I (OR 1.5 [1.1, 2.1]). HER2 status
was the largest predictor of trastuzumab use in the cohort, with HER2 equivocal,
negative or unknown status patients significantly less likely to receive treatment
than positive. Patients with advanced age at diagnosis (70y) had lower odds of
trastuzumab treatment compared to younger patients (OR 0.5 [0.3, 0.7]). Increasing
tumour grade was associated with higher odds of treatment. Treatment varied
significantly by LHIN. CONCLUSIONS: Despite limitations in centrally-reported tu-
mour pathology, we demonstrate that the use of confirmatory FISH testing in On-
tario was largely consistent with Canadian guidelines. Trastuzumab use in the
cohort was consistent with provincial guidelines on HER2 status in many patients,
though practice varies across LHINs.
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OBJECTIVES: To determine treatment patterns among individuals treated for un-
resectable stage III and IV melanoma in the Brazilian public and private health care
system. METHODS: A retrospective chart review was conducted in patients with
unresectable stage III and IV melanoma or relapsed between January 01 2008 and
December 31 2009. Patients had to have at least two months follow up in 12 private
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and public oncology centers in Brazil. RESULTS: Treatment was received by 161
eligible patients. The majority of patients were men (54.5%), and 30.3% were first
diagnosed at stage IV. Across up to three lines of treatment, 76.4% received sys-
temic therapy, 57.8% had surgery, 37.9% received radiotherapy and 9.3% received
supportive care. Among first line treatment, 30.4% received systemic treatment
only and 42.2% systemic in combination with surgery and/or radiotherapy. Second
line treatment was administered to 67 patients; of those, 88.1% had systemic treat-
ment, 9.0% received surgery, and 10.4% received radiotherapy. Only 26 patients
received third line treatment. Outside clinical trial, the most commonly-used drug
alone or in combination on first-line was Dacarbazine in both public (82.3%) and
private (68.0%) systems, followed by Interferon in the public system (25.8%) and
Interleukin in the private system (40.0%). The mean duration of systemic treatment
was 17.6 (95% confidence interval (CI) 14.1-21.2) weeks. For second line, the most
commonly-used drug was Paclitaxel (31.2%) for private system and Interferon and
Paclitaxel (both 24.0%) for public system. Mean systemic treatment duration was
11.8 (95% CI 7.2-16.4) weeks. In third line, Fotemustine and Dacarbazine were the
most commonly-used drugs. CONCLUSIONS: In Brazil the most common treat-
ment for unresectable stage III and IV melanoma is systemic treatment combined
with surgery and/or radiotherapy. The most comonly used agent in first line is
Dacarbazine; most common second line treatments are Paclitaxel and Interferon.
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OBJECTIVES: This study investigates the demographic and clinical characteristics
of patients with rheumatoid arthritis (RA) in Turkey and attempts to inform strat-
egies for the prevention, treatment, and support of RA. METHODS: In the present
study, 2359 patients with RA from 43 centers across Turkey and who were listed in
the Turkish League Against Rheumatism (TLAR) RA Registry were evaluated. Their
demographic and clinical data were recorded. Disease activity, functional status,
and radiographic damage were measured using the Disease Activity Score-28 (DAS-
28), the Health Assessment Questionnaire (HAQ), and van der Heijde modified
Sharp scoring method. Disease activity status was defined according to EULAR
criteria. RESULTS: The mean age of the sample was 51.6  12.5 years; 83.3% (1966)
were women and 16.7% (393) were men. The mean duration of education was
5.22  3.84 years, and 74.6% were homemakers. The mean disease duration was
11.9  8.7 years. Exercise habits, smoking habits, and alcohol consumption were
present in 7.1%, 16.2%, and 2.0%, respectively. The most common extra-articular
signs were those involving the eye (4.8%). Co-morbid diseases were observed in
57.1% of the patients. Nonbiological disease-modifying anti-rheumatic drugs
(DMARDs) were used by 91.0% of the patients, while 10.2% used biological DMARDs.
The mean DAS-28, HAQ, and Sharp scores were 4.04 1.46, 0.38 0.37, and 31.25
57.18, respectively. Patients who were in remission and had low disease activity
rates comprised 17.8% and 14.1% of the sample respectively, while 42.7% and 25.5%
had moderate and high disease activity rates, respectively. CONCLUSIONS: The
majority of patients with RA in Turkey are middle-aged and homemakers. The
level of education that important for compliance and success of treatment was
low. Despite the high use of DMARDs, the majority of patients have moderate
and high disease activities. This finding may suggest that the current treatment
is insufficient.
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OBJECTIVES: To investigate the clinical efficacy of NNC0109-0012 (anti-IL-20 mAb)
on physical function and disability in Rheumatoid Arthritis (RA) patients with ac-
tive disease on stable MTX but inadequate response (MTX-IR) in a phase 2a multi-
centre, randomised, double-blind, placebo-controlled, parallel group trial.
METHODS: Sixty-seven patients were randomised to once-weekly dosing of
NNC0109-0012 (n45) or placebo (n22) for 12 weeks and followed for additional 13
weeks. Of the 67 randomised patients 43 were Rheumatoid Factor (RF)- and anti-
Cyclic Citrullinated Protein (anti-CCP)-positive. Physical function and disability
was assessed by the patient-reported outcome measure Health Assessment Ques-
tionnaire – Disability Index (HAQ-DI). HAQ-DI was assessed weekly from baseline
to week 12 and additionally 3 times in the 13 weeks follow-up period. A mixed-
effects model repeated measures was fitted to change in HAQ-DI score including
treatment, time and interaction between treatment and time as fixed factors; base-
line HAQ-DI score and interaction between time and baseline HAQ-DI score as
continuous covariates and subject as random effect. RESULTS: Physical function
was not significantly improved for NNC0109-0012 compared to placebo after end of
treatment at 12 weeks (-0.26, p0.130) for all randomised patients. In RF- and
anti-CCP-positive patients physical function was significantly improved after both
12 and 25 weeks (p0.047 and p0.022, respectively). The estimated mean change
in HAQ-DI for RF- and anti-CCP-positive patients at 12 and 25 weeks were -0.60 and
-0.63 for NNC0109-0012, and -0.15 and -0.16 for placebo. The percentage of RF- and
anti-CCP-positive patients that achieved the criteria for the minimum clinical im-
portant difference (HAQ-DI0.22 units) at 25 weeks was significantly higher
(p0.046) for the NNC0109-0012 treated patients compared to placebo with 76% (22
of 29 patients) versus 43% (6 of 14 patients). CONCLUSIONS: Treatment with
NNC0109-0012 in MTX-IR RA patients on stable MTX effectively improved physical
function and disability in RF- and anti-CCP-positive patients.
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OBJECTIVES: To investigate the effects of NNC0109-0012 (anti-IL-20 mAb) on pa-
tient-reported pain and global disease activity in Rheumatoid Arthritis (RA) pa-
tients with active disease on stable MTX but inadequate response (MTX-IR) in a
clinical phase 2a trial. METHODS: 67 patients were randomised to once-weekly
dosing of NNC0109-0012 or placebo for 12 weeks and followed for 13 additional
weeks. 43 patients were Rheumatoid Factor (RF)- and anti-CCP-positive. The level
of pain and global disease activity was recorded on a 100 mm Visual Analogue Scale
(VAS) by the patients and assessed weekly from baseline to week 12 and addition-
ally 3 times in the 13 week follow up period. A mixed-effects model repeated
measures was fitted to the change for each of the VAS scales including treatment,
time and interaction between treatment and time as fixed factors; baseline VAS
score and interaction between time and baseline VAS score as continuous covari-
ates and subject as random effect. RESULTS:The average baseline pain and disease
activity were 67 and 68 mm (NNC0109-0012) and 71 and 70 mm (placebo). In all
randomised patients, pain was significantly reduced for NNC0109-0012 compared
to placebo after 12 weeks with a mean difference of -15 mm (p0.034) and was -13
mm (p0.046) at week 25. Global disease activity was significantly lower in all
randomised patients for NNC0109-0012 compared to placebo after 12 weeks with a
mean difference of -17 mm (p0.018) and maintained throughout the trial to week
25 with -14 mm (p0.031). For both pain and global disease activity the effects were
more pronounced in the RF- and anti-CCP-positive patients with a 1.5-2 fold larger
difference in effect size compared to placebo than was observed for all randomised
patients. CONCLUSIONS: Treatment with NNC0109-0012 (anti-IL-20 mAb) in
MTX-IR RA patients on stable MTX improved both pain and global disease activity.
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OBJECTIVES: Biologic therapy constitutes the current mainstay of rheumatoid ar-
thritis (RA) patients treatment who have inadequately responded to methotrexate
(MTX-IR). The objective of this study was to compare the relative efficacy, safety
and tolerability of abatacept subcutaneous (sc) vs. all relevant comparators in
MTX-IR patients with RA.METHODS:A systematic literature review identified clin-
ical trials investigating the efficacy, safety and tolerability of abatacept intravenous
and sc, adalimumab, certolizumab, etanercept, infliximab, golimumab, tocili-
zumab and anakinra in combination with MTX. The efficacy endpoints were:
Health Assessment Questionnaire (HAQ) change from baseline (CFB), American
College of Rheumatology (ACR) 20/50/70 response rates, and Disease activity score
28 joints (DAS28) remission rates defined as DAS282.6, after 24 and 52 weeks of
treatment. Safety and tolerability endpoints were: incidence of serious adverse
events (AE), infections, serious infections, withdrawals for any reason, due to AE or
due to lack of efficacy. Results were analysed using indirect treatment comparison
methods estimating the expected relative effect of treatments, and were expressed
as the difference in HAQ CFB and the Risk Ratio of achieving an outcome and
associated 95% Credible Intervals. RESULTS: The analysis of HAQ CFB showed that
abatacept sc is expected to show a relative efficacy comparable to other biologic.
Furthermore, abatacept sc showed ACR20/50/70 response rates and DAS28 remis-
sion rates comparable to other biologic treatments at both time periods. Abatacept
sc is expected to show a comparable safety and tolerability to other biologic treat-
ments, having a similar incidence of serious AE, infections, serious infections,
withdrawals for any reason, due to AE or due to lack of efficacy. CONCLUSIONS:
Considering the assumptions of a NMA, abatacept sc is expected to produce similar
HAQ CFB, ACR20/50/70 and DAS28 rates and a similar incidence of serious AE,
infections, serious infections and withdrawals compared to other biologics in
MTX-IR RA patients.
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OBJECTIVES: To compare treatment-related risks versus improvements in out-
comes in terms of net health benefit (NHB) for 3 treatments for moderate-to-severe
rheumatoid arthritis: the anti–tumor necrosis factor drugs (anti-TNFs) adali-
mumab (ADA) and infliximab (IFX), both in combination with methotrexate (MTX),
and MTX alone.METHODS:A simulation model was developed in which a cohort of
rheumatoid arthritis patients initiating treatment progressed at 6-month intervals
for 10 years or until withdrawal from therapy. NHB, measured in discounted qual-
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